136
Participants
Start Date
June 30, 2010
Primary Completion Date
September 30, 2013
Study Completion Date
March 10, 2017
Trivalent ganglioside vaccine
Patients will be given 10 injections of ganglioside vaccine plus adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
OPT-821
Patients will be given 10 injections of adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
Memorial Sloan-Kettering Cancer Center, New York
University of Pittsburg Hillman Cancer Center, Pittsburgh
Winship Cancer Institute at Emory Midtown, Atlanta
Cleveland Clinic, Cleveland
University of Michigan Hospital, Ann Arbor
University of Iowa Hospitals and Clinic, Iowa City
Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Chicago
Washington University School of Medicine, St Louis
University of Colorado (Denver), Denver
UCLA Medical Center, Los Angeles
Oregon Health & Sciences University, Portland
Fred Hutchinson Cancer Research Center/Seattle Cancer Care, Seattle
Dana Farber Cancer Institute, Boston
Lead Sponsor
MabVax Therapeutics, Inc.
INDUSTRY